アンジオテンシンII型2受容体の過剰発現は,心筋梗塞後の左心室機能を保ちます
Zequan Yang1, Christina M Bove, Brent A French
1Department of Medicine and the Cardiovascular Research Center, University of Virginia Health System, Charlottesville 22908, USA.
Circulation
|July 3, 2002
まとめ
トランスジェニックマウスの心臓AT2-R過剰発現は,心筋梗塞後の左心室内静脈機能を改善した. これは,AT2-Rが心臓の改造に保護的役割を果たしていることを示唆しています.
科学分野:
- 心血管科学の研究について
- 分子心臓病学 分子心臓病学
- 再生医学は,再生医療である.
背景:
- 左心室 (LV) の改造におけるアンジオテンシンII型2受容体 (AT2-R) の役割は刺激に依存しています.
- 心筋梗塞 (MI) の後の再建に対するAT2-Rの影響を調査することは極めて重要です.
研究 の 目的:
- 心臓AT2-R過剰発現がMI後のLVリフォームを弱めるという仮説を検証する.
- 心臓発作後のAT2-R過剰発現による心臓の機能的,構造的変化を評価する.
主な方法:
- 心臓MRIは,ワイルドタイプ (WT) とAT2-Rトランスジェニック (TG) のマウスにおけるLVリモデリングを評価するために使用されました.
- 測定対象は,ベースラインでのLV質量,体積,エジェクション分数,心臓発作のサイズ,および28日後の心臓発作でした.
- ヘモダイナミックパラメータと地域壁機能も分析されました.
主要な成果:
- ベースラインのLV機能は,WTマウスと比較して,TGマウスで高かった.
- 心筋梗塞の大きさは,MI後のグループ間で類似していました.
- TGマウスは,WTマウスと比較して,MI後の28日後に,LVシストリック機能 (より高いEF,より低いESVI) が有意に保存され,地域機能が改善されました.
- 血圧とLV dP/dtは28日目TGマウスでも高かった.
結論:
- 心臓AT2-R過剰発現は,ベースラインでのLVシストリック機能を有意に改善します.
- AT2-Rの過剰発現は,心筋梗塞後の再構築中に心臓機能を保ちます.
- AT2-Rは,心筋梗塞後の不良心改造を緩和するための治療目標である可能性があります.
さらに関連する動画
関連する概念動画
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
3.0K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:29Heart Failure II: Pathophysiology
2.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.1K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
798
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
798